

Thomas Jefferson University Jefferson Digital Commons

House Staff Quality Improvement and Patient Safety Conference (2016-2019)

Quality Improvement & Patient Safety Initiatives

5-31-2017

Quality Review of Irradiated Cellular Blood Product Orders

Matthew Grzywinski Sidney Kimmel Medical College, Thomas Jefferson University

Vandy Ly, MD Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/patientsafetyposters

Part of the Medicine and Health Sciences Commons
<u>Let us know how access to this document benefits you</u>

Recommended Citation

Grzywinski, Matthew and Ly, MD, Vandy, "Quality Review of Irradiated Cellular Blood Product Orders" (2017). *House Staff Quality Improvement and Patient Safety Conference (2016-2019)*. Poster 46. https://jdc.jefferson.edu/patientsafetyposters/46

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in House Staff Quality Improvement and Patient Safety Conference (2016-2019) by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



Quality Review of Irradiated Cellular Blood Product Orders

Matthew Grzywinski¹, Vandi Ly, M.D.²

Background

Transfusion-associated graft-versus-host disease (TA-GVHD) is an immunological response between a donor's transfused T cells and the recipient's immune defense. The risk of TA-GVHD increases with relatively large transfusions of lymphocytes (e.g. transfusion in infants or granulocyte transfusion) or immunocompromised individuals. The risk of TA-GVHD is mitigated by irradiating cellular blood components to prevent donor T lymphocyte proliferation.

Irradiation of cellular blood components is managed differently amongst institutions. Factors to consider in the irradiation process include technologist time. Technologists prepare and perform irradiation of the cellular blood products. This can be a labor intensive process. Cost is another factor that includes the cost of the irradiation indicators that are placed on the units and the labor in providing this service. Irradiation also shortens the shelf life of the cellular blood component to 28 days. If the shelf life was less than 28 days then irradiation does not extend the shelf life to 28 days (e.g. shelf life 14 days, post-irradiation remains 14 days). At Thomas Jefferson University Hospital, the Blood Bank irradiates blood products only upon request, then reviews the initial orders to determine if irradiation is indeed indicated. The decision whether irradiation is appropriate is determined by having medical coverage review the requests.

RAD-SURE®	OPERATOR	DATE:
25 Gy INDICATOR	NOT	IRRADIATED
ISP TECHNOLOGIES	INC. LOT NO	EXP.
BEFOR	E IRRAD	IATION




Objective

Our goal is to educate house staff on the indications for irradiated blood products. We hope to reduce the number of inappropriate irradiation orders to less than 50% of the total orders for irradiated blood products and to be followed up over time.

Review of Inappropriate Orders

Irradiated blood product orders flagged for medical coverage review from July 2016 to March 2017 revealed 34 of the 55 orders were inappropriate. For each incorrect order, clinician name, clinician service, hospital unit, transfusion indications, and reason for irradiation were recorded. The inappropriate orders were submitted by 31 clinicians (24 medicine residents, two anesthesia residents, two otolaryngology residents, two nurse practitioners, and one attending physician). Three clinicians submitted two inappropriate irradiation orders. The clinicians ordered the irradiated cellular blood products because the patient had a history of cancer or was on immunosuppressive therapy. Some clinicians accidentally requested irradiated cellular blood products.

Between March 1, 2017 and May 1, 2017, two orders for irradiated cellular blood products were flagged for medical coverage review. In one of those requests, irradiated cellular blood products were not indicated.





Interventions to Decrease Inappropriate Orders

Two interventions were undertaken to decrease the number of inappropriate irradiation orders.

A polite and professional email was sent to the clinicians who submitted the inappropriate irradiation orders from July 2016 to March 2017. The email informed the clinician that they submitted an inappropriate irradiation order, provided them with a table of irradiation blood product indications, and additional resources. This email was sent on February 27, 2017.

	lood products. Below is a table of indications for irradiated blood products. We ha ad a more comprehensive set of quidelines from the British Committee for Standa
	logy Blood Transfusion Task Force, and an article detailing the changes that occu of the irradiation process.
Ind	ication for irradiation of cellular blood components for the prevention of
	transfusion-associated graft-versus-host disease
Absolute i	
	ith congenital cellular immune deficiency
of inherite	born to families with previous birth of an offspring with a known or suspected forn d immunodeficiency
Allogeneic	or autologous hematopoietic stem cell recipients
Hodgkin's	disease
Granulocy	te transfusions
Intrauterin	e transfusions (IUT)
Transfusio	ins to neonates who have received IUT
Transfusio	ins from biologic relatives
Probable i	ndications
Premature	neonates weighing <1200 g
Hematolog	gic malignancies other than Hodgkin lymphoma treated with cytotoxic agents
HLA-matc	hed and/or crossmatch-compatible platelet concentrate transfusions
	eceiving high-dose chemotherapy, radiation therapy, and/or aggressive erapy, including all patients receiving fludarabine or other purine analogs
Mintz, Paul I Print.	D. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press, 201
	free to contact us if you would like additional information or have any questions.

A pocket card was also created. The card contained a table of indications for irradiated cellular blood products and contact information for the Jefferson Blood Bank to encourage collaboration between house staff and the Blood Bank. The card will be distributed on June 13, 2017 to Internal Medicine house staff.

Matt Grzywinski, SKMC Class of 2019

Indication for irradiation of cellular blood components for the prevention of]
transfusion-associated graft-versus-host disease Absolute indications	
Patients with congenital cellular immune deficiency	-
Neonates born to families with previous birth of an offspring with a known or suspected form of inherited immunodeficiency	-
Allogeneic or autologous hematopoietic stem cell recipients	Thomas Jefferson University Blood Ban 8220 Gibbon Building
Hodgkin's disease	
Granulocyte transfusions	
Intrauterine transfusions (IUT)	
Transfusions to neonates who have received IUT	215-955-6356
Transfusions from biologic relatives	210 000 0000
Probable indications	
Premature neonates weighing <1200 g	1
Hematologic malignancies other than Hodgkin lymphoma treated with cytotoxic agents]
HLA-matched and/or crossmatch-compatible platelet concentrate transfusions]
Patients receiving high-dose chemotherapy, radiation therapy, and/or aggressive immunotherapy, including all patients receiving fludarabine or other purine analogs	
	Mintz, Paul D. Transfusion Therapy: Clinical Principles and Practice. Betheeds MD: AABB Press, 2011

Discussion

Next Steps

- Dr. Julie Karp, Associate Director of the Thomas Jefferson University Blood Bank, will give an educational lecture to the Department of Medicine residents on blood products (including irradiated cellular blood products) on June 13, 2017
- Irradiated cellular blood product orders will be reviewed to determine if the number of inappropriate orders decrease over time.

Possible Further Interventions

- · Email all Jefferson residents informing them of the indications for irradiated cellular blood products.
- Email Jefferson faculty informing them of the indications for irradiated cellular blood products.
- Present the findings of this research and the indications for irradiated cellular blood products to Jefferson residents at seminars, conferences, or meetings.

Limitations

- Only the clinician who submitted the inappropriate irradiation order was contacted, not the entire care team
- The preliminary post-intervention data may not be representative since residents gain experience during the year.
- Only one year of inappropriate orders were reviewed.

References

Mintz, Paul D. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press (2011). Print.

Gehrie, Eric A and Dunbar Nancy M. Modifications to Blood Components: When to Use them and What is the Evidence? Hematol Oncol Clin N Am 30 (2016) 653-663. Adams, Faiega et al. Biochemical Storage Lesions Occurring in Nonirradiated and Irradiated Red Blood Cells: A Brief Review. BioMed Research International (2015). Hauck-Dlimi, Barbra et al. Influence of Early Irradiation on In Vitro Red Blood Cell (RBC) Storage Variables of Leucoreduced RBCs in Additive Solution SAG-M. Vox Sanguinis 110 (2016) 362-368.

Kopolovic, Ilana et al. A Systematic Review of Transfusion-Associated Graft-Versus-Host Disease. Transfusion Medicine 126 (2015) 406-414.

Acknowledgements

The authors would like to acknowledge the help of Dr. Julie Karp and Mary Harach for their help on this project.